Replies to post #20821 on Synaptogenix Inc (SNPX)

[runncoach]

Yes he gave some great input on the Anavex trial and I see others on social media have slammed the presentation and may even have been pulled from their website. This part of Doc's post is what I was referring to last night and I can't get past this: "The slides and/or PR also do not report the co-primary endpoint (ADCS-ADL) numbers just a +3.5 point responder analysis which was not the endpoint." Once again it looks like a miss on one of the primary endpoints with stat significance in the other which barely reaches the threshold. Not the stuff a pivotal trial is made of IMO. Titration is clearly an issue and seems they don't know what the best dose is. Not sure how that's handled moving forward. I'm sure it will end up being data mined and show good subgroup results. Essentially what many of us predicted (along with a murky PR)... Mixed results and shows the drug does something but along ways off from D-day. JMHO